Aptorum gets Nasdaq minimum bid price deficiency notice

Aptorum Group Limited reported that Nasdaq has notified the company it is not in compliance with the exchange’s minimum bid price requirement of $1 per share under Listing Rule 5550(a)(2).

Rhea-AI Filing Summary

Aptorum Group Limited reported that Nasdaq has notified the company it is not in compliance with the exchange’s minimum bid price requirement of $1 per share under Listing Rule 5550(a)(2). The notice does not immediately affect the listing or trading of Aptorum’s shares.

The company has a 180-calendar-day grace period, until September 1, 2026, to regain compliance. During this time, Aptorum plans to evaluate options to restore compliance, including a potential reverse stock split, and states it is committed to maintaining its Nasdaq listing.

Insights

Equity markets analyst

Nasdaq bid-price non-compliance adds listing risk for Aptorum.

Aptorum Group Limited has fallen below Nasdaq’s $1 minimum bid price requirement, triggering a formal deficiency notice under Listing Rule 5550(a)(2). The company’s shares continue to trade, so there is no immediate change to liquidity or market access.

Nasdaq has granted a 180-day grace period ending on September 1, 2026 for Aptorum to regain compliance. The company states it will consider all available options, explicitly including a possible reverse stock split, which can boost share price without changing overall equity value.

The key uncertainty is whether market trading will naturally restore the bid above $1 or whether a corporate action will be needed. Subsequent company communications and any announced reverse split plan will further clarify how Aptorum intends to secure its Nasdaq listing over this compliance window.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aptorum Group Limited (APM) announce in its latest update?

Aptorum Group Limited announced it received a Nasdaq notification that its shares no longer meet the $1 minimum bid price requirement. The company emphasized that this notice does not immediately affect the listing or trading of its shares on the Nasdaq Capital Market.

Why did Aptorum Group Limited (APM) receive a Nasdaq minimum bid price deficiency notice?

Aptorum received the notice because its share price failed to meet Nasdaq’s required minimum bid price of $1 per share under Listing Rule 5550(a)(2). This rule is one of Nasdaq’s continued listing standards for companies on the Nasdaq Capital Market.

How long does Aptorum Group Limited (APM) have to regain Nasdaq bid price compliance?

Aptorum has a 180-calendar-day grace period, ending on September 1, 2026, to regain compliance with Nasdaq’s $1 minimum bid price rule. During this window, the company can pursue measures that restore its share price to the required level.

Does the Nasdaq deficiency notice immediately affect trading in Aptorum Group (APM) shares?

The Nasdaq deficiency notice does not immediately affect the listing or trading of Aptorum’s shares. The stock continues to trade on Nasdaq while the company works within the 180-day grace period to regain compliance with the minimum bid price requirement.

What actions might Aptorum Group Limited (APM) take to restore Nasdaq compliance?

Aptorum stated it will evaluate all available options to restore compliance, including a potential reverse stock split. A reverse split would reduce the number of shares outstanding while proportionally increasing the share price to meet Nasdaq’s $1 minimum bid rule.

What is the key Nasdaq rule affecting Aptorum Group Limited (APM)?

The key rule is Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1 per share for continued listing on the Nasdaq Capital Market. Aptorum’s recent trading below this threshold triggered the formal deficiency notification from Nasdaq.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 04:30 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-38764

APTORUM GROUP LIMITED

17 Hanover Square

London W1S 1BN, United Kingdom

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒     Form 40-F ☐

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release – Aptorum Group Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Aptorum Group Limited
Date: March 6, 2026	By:	/s/ Ian Huen
		Name:	Ian Huen
		Title:	CEO

2

Exhibit 99.1

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Hong Kong, March 6, 2026 – Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated March 5, 2026 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2).

The notification does not immediately affect the listing or trading of the company’s shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until September 1, 2026, to regain compliance with the noted listing requirement.

During this period, Aptorum Group Limited intends to evaluate all available options to restore compliance, including, if necessary, a reverse stock split. The company is committed to maintaining its Nasdaq listing and will take all reasonable measures to achieve compliance within the stipulated time frame.

About Aptorum Group Limited

Aptorum Group Limited is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. These statements reflect the company’s current expectations and projections about future events and are based on assumptions. Actual results may differ materially from those projected.

For further information, please contact: investor.relations@aptorumgroup.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE - APTORUM GROUP LIMITED RECEIVES NASDAQ NOTIFICATION REGARDING MIN 3.7 KB